Notice of Information: NIAAA Clinical Medications Development Testing Program
Notice Number:

Key Dates

Release Date:

March 24, 2021

Related Announcements


Issued by

National Institute on Alcohol Abuse and Alcoholism (NIAAA)


The purpose of this notice is to raise awareness of the medications development contract clinical program for testing promising new medications to treat alcohol use disorder (AUD) in alcohol interaction and Phase II human laboratory and clinical trials. Potential drug candidates for the program arise from many sources including NIAAA-supported investigators, NIH initiatives, and pharmaceutical company research.

Program Information

The NIAAA Medications Development contract-supported clinical program is designed to bridge the gap between pre-clinical and Phase III testing and de-risk medications development for industry, small businesses, and academic partners by leveraging government resources to help accelerate bringing promising new/re-purposed medications to treat AUD to market. Specifically, this program supports alcohol interaction studies and Phase II human laboratory studies and clinical trials. For consideration, drug candidates must be well characterized, have a robust safety profile, and have shown promising efficacy through pre-clinical testing. Drug candidates that have been tested extensively in clinical settings for the treatment of AUD will not be considered.


Please direct all inquiries to:

Raye Z. Litten, Ph.D.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone: 301-443-0636

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices